The antitumor efficacy of the cis-diamminedichloroplatinum (cisDDP) and 5 fluorouracil (5FU) combination was evaluated in a panel of eight human colorectal carcinoma xenografts. Tumors differed in origin (primary or metastatic), differentiation degree and chemotherapy treatment. Xenografts were treated with repeated i.v. injections of cisDDP, 5FU, or both drugs at 24-h interval. Compared with controls, cisDDP achieved a significant tumor growth inhibition in five out of eight tumor lines, and 5FU in four out of seven. One of two unresponsive tumor lines was significantly inhibited by the combination, that was also more effective than either drug alone (p < 0.05) in one responsive xenograft. Comparing the effects of the combination according to which drug was administered first, lower drug doses were tolerated using the cisDDP-5FU sequence, but the antitumor effects were similar at equitoxic doses. These results indicate a potential therapeutic benefit of the cisDDP-5FU combination for colorectal carcinoma patients and show that toxicity of the combination Is influenced by the drug sequence.
Get full access to this article
View all access options for this article.
References
1.
ArrickB.A., NathanCF.: Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res., 44: 4224–4232, 1984.
2.
BergeratJ.P., DrewinkoB., CorryP., BarlogieB., HoD.H.: Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res., 41: 25–30, 1981.
3.
BraakhuisB.J.M., SchoeversE.J., HeinermanE.C.M., Sne-euwloperG., SnowG.B.: Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate. Br. J. Cancer, 48: 711–716, 1983.
4.
CantrellJ., HartR., TaylorR., HarveyJ.: A phase II trial of continuous infusion (CI) 5-FU and weekly low dose cisplatin (DDP) in colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 5, 326, p. 84, 1986.
5.
De SimoneP.A., DavilaE., JochimsenP.R., BartolucciA.A.: High-dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a southeastern cancer study group trial. Cancer Treat. Rep., 70: 1229–1230, 1986.
6.
DrewinkoB., DipasqualeM.A., YangL.Y., BarlogieB., TrujilloJ.M.: The synergistic lethal interaction of cis-diam-minedichloroplatinum and natural nucleosides is related to increased DNA cross-links. Chem. Biol. Interact., 55: 1–12, 1985.
7.
DyC., GilA., AlgarraS.M., AparicioL.A., CalvoF., HerranzP.: Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma. Cancer Treat. Rep., 70: 465–468, 1986.
GeranR.I., GreenbergN.H., MacdonaldM.M., SchumacherA.M., AbbottB.J.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3: 1–88, 1972.
10.
HellersteinS., RosenS., KiesM., TsangT., ShawJ.: Diam-minedichloroplatinum and 5-Fluorouracil combined chemotherapy of epidermoid esophageal cancer. Proc. Am. Soc. Clin. Oncol., 2, C-497, p. 127, 1983.
11.
HoughtonJ.A., HoughtonP.J.: The suitability and use of human tumor xenografts. In: Rodent tumor models in experimental cancer therapy.KallmanR.F. (ed.), 199–204. Pergamon Press, New York, 1987.
12.
KrishanA.: Rapid flow. cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell. Biol., 66: 188–193, 1975.
13.
LehaneD.E., ZublerM.A., LaneM., SmithF.E.: Intraarterial cisplatin in metastatic or recurrent colon cancer. Proc. Am. Soc. Clin. Oncol., C-365, p. 94, 1982.
14.
LeichmanL., SeydelH.G., SteigerZ.: Preoperative adjuvant therapy for squamous cell cancer (SCC) of the esophagus. Proc. Am. Soc. Clin. Oncol., 3, C-575, p. 147, 1984.
15.
LindmoT., SteenH.B.: Characteristics of a simple, high resolution flow cytometer based on a new flow configuration. Biophys. J., 28: 33–44, 1979.
16.
MoertelC.G.: Chemotherapy of gastrointestinal cancer. N. Engl. J. Med., 299: 1049–1052, 1978.
17.
PosnerM.R., BelliveauJ.F., WeitbergA.B., SabbathK., WiemannM.C., CummingsF.J., CalabresiP.: Continuous-infusion cisplatin and bolus 5-Fluorouracil in colorectal carcinoma. Cancer Treat. Rep., 71: 975–977, 1987.
18.
PratesiG., GianniL., ManzottiC., ZuninoF.: Sequence dependence of the antitumor and toxic effects of 5-Fluoro-uracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother. Pharmacol., 21: 237–240, 1988.
19.
RooneyM., KishJ., JacobsJ., KinzieJ., WeaverA., CrissmanJ., Al-SarrafM.: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 12-hour 5-FU infusion and cisplatin. Cancer, 55: 1123–1128, 1985.
20.
ScanlonK.J., NewmanE.M., LuY., PriestD.G.: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci., 83: 8923–8925, 1986.
21.
ShepardK.V., FaintuchJ., BitranJ.D., SweetD.L., RobinE., LevinB.: Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU. Cancer Treat. Rep., 69: 123–124, 1985.
22.
ThyssA., SchneiderM., SantiniJ., CaldaniC., VallicioniJ., ChauvelP., DemardF.: Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br. J. Cancer, 54: 755–760, 1986.
23.
ViettiT., CoulterD., ValerioteF.: Interval and sequence dependent lethal effects of cis-diamminedichloroplatinum (cis-pt) in combination with other agents. Proc. Am. Assoc. Cancer. Res. and Am. Soc. Clin. Oncol., 20, 818, p. 202, 1979.
